Low-Dose Intravenous and Subcutaneous CIS43LS Monoclonal Antibody for Protection against Malaria (VRC 612 Part C): A Phase I, Adaptive Trial

Adults aged 18–50 years with no previous malaria vaccinations or infections received the monoclonal antibody CIS43LS in a single, open-label dose of 1 mg/kg, 5 mg/kg, or 10 mg/kg intravenously, or 5 mg/kg or 10 mg/kg subcutaneously.